FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA Open to Single Phase 3 for Netherton Syndrome Drug

Quoin Pharmaceuticals says FDA has signaled openness to a streamlined development path for its rare disease candidate QRX003, indicating that a single...

latest-news-card-1
Human Drugs

Beam Eyes Accelerated Approval for Genetic Disease Therapy

Beam Therapeutics says it will advance its base-editing therapy BEAM-302 into pivotal development to seek accelerated approval for treating Alpha-1 An...

latest-news-card-1
Human Drugs

4 Observations on Micro Labs 483

FDA releases the form FDA-483 issued following an inspection at the Micro Labs drug manufacturing facility in Bengaluru, Karnataka, India.

latest-news-card-1
Human Drugs

Corcepts Lifyorli Combo in Platinum-Resistant Ovarian Cancer Approved

FDA approves Corcept Therapeuticss cortisol-modulating drug Lifyorli (relacorilant) in combination with nab-paclitaxel for patients with platinum-resi...

latest-news-card-1
Human Drugs

HELP Republican Senators Urge FDA Mifepristone Action

Five Republicans on the Senate HELP Committee urge FDA to crack down on companies they say are illegally selling chemical abortion drugs in the U.S.

latest-news-card-1
Medical Devices

5 Key Points in New FDA Weight Loss Device Guidance

Two Hogan Lovells attorneys highlight five areas in a new FDA final guidance on weight loss devices.

latest-news-card-1
Human Drugs

4 CGMP Issues in the Yangzhou Company Inspection

FDA warns Chinas Yangzhou H&R Plastic Daily Chemical Company about CGMP violations in its production of finished drugs.

latest-news-card-1
Medical Devices

QS Violations at IsoTis OrthoBiologics

FDA warns Irvine, CA-based IsoTis OrthoBiologics about Quality System violations in its production of Accell-branded resorbable calcium salt bone void...

latest-news-card-1
FDA General

More Conflict of Interest Transparency Needed: GAO

The Government Accountability Office recommends that FDA take steps to publicly disclose how it resolves conflict of interest and appearance issues fo...

latest-news-card-1

Meaning of Prasads Departure Debated

Three experts express differing views on the reasons for and the impact of the departure of CBER director Vinay Prasad from FDA for a second time.